[{"id":"917b48fd-6760-442b-9dca-351ad6f6d491","acronym":"","url":"https://clinicaltrials.gov/study/NCT02299141","created_at":"2021-01-17T17:53:09.705Z","updated_at":"2025-02-25T15:33:17.802Z","phase":"Phase 2","brief_title":"Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02299141","lead_sponsor":"Washington University School of Medicine","biomarkers":" EGFR • ALK • TP53 • FLT1","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • RET rearrangement","tags":["EGFR • ALK • TP53 • FLT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • RET rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 05/07/2015","start_date":" 05/07/2015","primary_txt":" Primary completion: 01/09/2020","primary_completion_date":" 01/09/2020","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-11"},{"id":"a432e095-2d79-44fd-b0b9-8a64e94ebfdd","acronym":"NintNivo","url":"https://clinicaltrials.gov/study/NCT04046614","created_at":"2021-07-05T17:24:28.801Z","updated_at":"2024-07-02T16:35:20.663Z","phase":"Phase 1/2","brief_title":"Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology","source_id_and_acronym":"NCT04046614 - NintNivo","lead_sponsor":"AIO-Studien-gGmbH","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 05/25/2018","start_date":" 05/25/2018","primary_txt":" Primary completion: 05/23/2023","primary_completion_date":" 05/23/2023","study_txt":" Completion: 09/15/2023","study_completion_date":" 09/15/2023","last_update_posted":"2024-02-06"},{"id":"77fe0c19-ea57-4747-8575-926fa32a925b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03377023","created_at":"2021-01-18T16:39:56.672Z","updated_at":"2024-07-02T16:35:22.265Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer","source_id_and_acronym":"NCT03377023","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" EGFR • BRAF • ALK","pipe":" | ","alterations":" BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement","tags":["EGFR • BRAF • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 02/02/2018","start_date":" 02/02/2018","primary_txt":" Primary completion: 11/28/2024","primary_completion_date":" 11/28/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-01-25"},{"id":"4df095d5-85b3-400e-86eb-3ef2e22e4f1b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03513484","created_at":"2021-01-18T17:17:32.073Z","updated_at":"2024-07-02T16:35:25.364Z","phase":"Phase 1","brief_title":"Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT03513484","lead_sponsor":"Northwestern University","biomarkers":" FLT3 • KMT2A • CD34 • HOXA9 • FGF2","pipe":" | ","alterations":" HOXA9 overexpression","tags":["FLT3 • KMT2A • CD34 • HOXA9 • FGF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HOXA9 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e azacitidine • nintedanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 11/14/2018","start_date":" 11/14/2018","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2023-12-22"},{"id":"2bafa7f6-34b1-49c6-949e-a3fe4e4c7ea7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06071013","created_at":"2023-10-06T14:11:38.244Z","updated_at":"2024-07-02T16:35:34.351Z","phase":"Phase 2","brief_title":"Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients","source_id_and_acronym":"NCT06071013","lead_sponsor":"China Medical University Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e erlotinib • Gilotrif (afatinib) • gefitinib • nintedanib"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 08/27/2026","primary_completion_date":" 08/27/2026","study_txt":" Completion: 08/27/2026","study_completion_date":" 08/27/2026","last_update_posted":"2023-10-06"},{"id":"340f6d59-f15f-42d4-9713-7b54b00fa082","acronym":"","url":"https://clinicaltrials.gov/study/NCT05444998","created_at":"2022-07-06T15:54:31.792Z","updated_at":"2024-07-02T16:36:07.674Z","phase":"Phase 2","brief_title":"Neoadjuvant Inituomab, Pyrrolidone and Nab-paclitaxel for HER2+Breast Cancer","source_id_and_acronym":"NCT05444998","lead_sponsor":"Xijing Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e albumin-bound paclitaxel • cyclophosphamide • epirubicin • nintedanib"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 08/31/2023","primary_completion_date":" 08/31/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-07-06"},{"id":"2ea36251-0a37-4f01-ac02-6a770fb828cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03292250","created_at":"2021-01-18T16:15:56.076Z","updated_at":"2024-07-02T16:36:14.544Z","phase":"Phase 2","brief_title":"Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]","source_id_and_acronym":"NCT03292250","lead_sponsor":"Seoul National University Hospital","biomarkers":" HER-2 • FGFR","pipe":" | ","alterations":" CDKN2A negative","tags":["HER-2 • FGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDKN2A negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Piqray (alpelisib) • Verzenio (abemaciclib) • Imjudo (tremelimumab-actl) • nintedanib • Pozenveo (poziotinib)"],"overall_status":"Completed","enrollment":" Enrollment 180","initiation":"Initiation: 09/10/2017","start_date":" 09/10/2017","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/10/2022","study_completion_date":" 03/10/2022","last_update_posted":"2022-03-29"},{"id":"3d2db7e5-d412-4a60-8f14-a799533e6de8","acronym":"REFRACT","url":"https://clinicaltrials.gov/study/NCT02531737","created_at":"2021-01-18T12:14:33.882Z","updated_at":"2024-07-02T16:36:26.711Z","phase":"Phase 2","brief_title":"Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer","source_id_and_acronym":"NCT02531737 - REFRACT","lead_sponsor":"University Hospital, Limoges","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 59","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 09/26/2020","primary_completion_date":" 09/26/2020","study_txt":" Completion: 09/26/2020","study_completion_date":" 09/26/2020","last_update_posted":"2021-08-10"},{"id":"61d416f9-d3f4-45bc-ac3a-62bd0c2f18f0","acronym":"NIPAWILMA","url":"https://clinicaltrials.gov/study/NCT02308553","created_at":"2021-01-18T10:55:51.430Z","updated_at":"2024-07-02T16:36:40.063Z","phase":"Phase 1/2","brief_title":"Efficacy and Safety of Nintedanib Combined With Paclitaxel Chemotherapy for Patients With BRAF wt Metastatic Melanoma","source_id_and_acronym":"NCT02308553 - NIPAWILMA","lead_sponsor":"Prof. Dr. med. Dirk Schadendorf","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600 • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 03/17/2015","start_date":" 03/17/2015","primary_txt":" Primary completion: 10/17/2019","primary_completion_date":" 10/17/2019","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2020-10-14"},{"id":"6af7f264-75bc-4281-b06e-4733e8249335","acronym":"","url":"https://clinicaltrials.gov/study/NCT01484080","created_at":"2021-01-18T06:12:09.373Z","updated_at":"2024-07-02T16:36:50.926Z","phase":"Phase 1/2","brief_title":"Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates","source_id_and_acronym":"NCT01484080","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 140","initiation":"Initiation: 10/01/2011","start_date":" 10/01/2011","primary_txt":" Primary completion: 11/01/2013","primary_completion_date":" 11/01/2013","study_txt":" Completion: 04/01/2014","study_completion_date":" 04/01/2014","last_update_posted":"2020-01-27"},{"id":"e78935a3-7a1c-448f-ba24-50bfb7b1c556","acronym":"","url":"https://clinicaltrials.gov/study/NCT02619162","created_at":"2021-01-18T12:43:30.392Z","updated_at":"2024-07-02T16:36:57.874Z","phase":"Phase 1","brief_title":"Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics","source_id_and_acronym":"NCT02619162","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" FGFR1","pipe":"","alterations":" ","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 11/01/2017","primary_completion_date":" 11/01/2017","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2019-07-23"},{"id":"00ae37df-56ff-4096-b9b9-a66716864471","acronym":"","url":"https://clinicaltrials.gov/study/NCT01669798","created_at":"2021-01-18T07:13:23.073Z","updated_at":"2024-07-02T16:37:06.063Z","phase":"Phase 2","brief_title":"BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer","source_id_and_acronym":"NCT01669798","lead_sponsor":"AA Secord","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 09/10/2017","primary_completion_date":" 09/10/2017","study_txt":" Completion: 02/01/2018","study_completion_date":" 02/01/2018","last_update_posted":"2018-10-16"},{"id":"a05c3ff4-1d35-42ee-99b9-d78d41b00e4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02835833","created_at":"2021-01-18T13:55:01.923Z","updated_at":"2024-07-02T16:37:09.067Z","phase":"Phase 1","brief_title":"Study of Nintedanib Plus Bevacizumab in Advanced Solid Tumors","source_id_and_acronym":"NCT02835833","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" VEGFA • PIGF • FGF","pipe":"","alterations":" ","tags":["VEGFA • PIGF • FGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 06/09/2016","start_date":" 06/09/2016","primary_txt":" Primary completion: 04/14/2018","primary_completion_date":" 04/14/2018","study_txt":" Completion: 06/14/2018","study_completion_date":" 06/14/2018","last_update_posted":"2018-07-10"},{"id":"7964f8ed-42a6-41d3-b6a4-fcbb86016cb3","acronym":"LUME-Colon 1","url":"https://clinicaltrials.gov/study/NCT02149108","created_at":"2021-01-18T09:59:08.740Z","updated_at":"2024-07-02T16:37:19.683Z","phase":"Phase 3","brief_title":"Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)","source_id_and_acronym":"NCT02149108 - LUME-Colon 1","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 768","initiation":"Initiation: 09/25/2014","start_date":" 09/25/2014","primary_txt":" Primary completion: 05/13/2016","primary_completion_date":" 05/13/2016","study_txt":" Completion: 08/25/2016","study_completion_date":" 08/25/2016","last_update_posted":"2017-07-21"},{"id":"9f53334d-5aa1-43fc-b5fd-f596e79c499e","acronym":"","url":"https://clinicaltrials.gov/study/NCT01948141","created_at":"2021-01-18T08:49:51.923Z","updated_at":"2024-07-02T16:37:21.269Z","phase":"Phase 2","brief_title":"Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens","source_id_and_acronym":"NCT01948141","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" FGFR1","pipe":" | ","alterations":" FGFR1 amplification","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/30/2014","start_date":" 01/30/2014","primary_txt":" Primary completion: 08/16/2016","primary_completion_date":" 08/16/2016","study_txt":" Completion: 08/16/2016","study_completion_date":" 08/16/2016","last_update_posted":"2017-06-08"},{"id":"f29597ba-4e28-4f5a-818d-718195cbece0","acronym":"MEGAN","url":"https://clinicaltrials.gov/study/NCT02856867","created_at":"2021-01-18T14:01:23.154Z","updated_at":"2024-07-02T16:37:22.707Z","phase":"Phase 2","brief_title":"Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)","source_id_and_acronym":"NCT02856867 - MEGAN","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" HER-2 • FGFR2 • FUS","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • FGFR2 • FUS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • nintedanib • leucovorin calcium"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 06/01/2019","primary_completion_date":" 06/01/2019","study_txt":"","study_completion_date":"","last_update_posted":"2017-05-09"},{"id":"9f6b35bb-6e58-44a8-ab0d-fd918e1ca3da","acronym":"","url":"https://clinicaltrials.gov/study/NCT00710762","created_at":"2023-10-15T04:12:34.077Z","updated_at":"2024-07-02T16:37:29.793Z","phase":"Phase 2","brief_title":"A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer","source_id_and_acronym":"NCT00710762","lead_sponsor":"Boehringer Ingelheim","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 89","initiation":"Initiation: 03/01/2006","start_date":" 03/01/2006","primary_txt":" Primary completion: 09/01/2008","primary_completion_date":" 09/01/2008","study_txt":" Completion: 03/01/2014","study_completion_date":" 03/01/2014","last_update_posted":"2016-08-15"},{"id":"c276f837-8067-4b8a-a5b7-5fd0326b0345","acronym":"","url":"https://clinicaltrials.gov/study/NCT02152059","created_at":"2021-01-18T10:00:14.306Z","updated_at":"2025-02-25T16:24:19.411Z","phase":"Phase 2","brief_title":"A Study to Evaluate the Good and Bad Effects of BIBF1120 in Small Cell Lung Cancer Patients Who Have Previously Benefited From First-line Platinum-based Chemotherapy","source_id_and_acronym":"NCT02152059","lead_sponsor":"AHS Cancer Control Alberta","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e nintedanib"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 07/01/2014","start_date":" 07/01/2014","primary_txt":" Primary completion: 07/01/2016","primary_completion_date":" 07/01/2016","study_txt":" Completion: 07/01/2016","study_completion_date":" 07/01/2016","last_update_posted":"2016-07-06"},{"id":"34b9c1f0-9514-4521-99d2-b19d1ac14a1c","acronym":"BARIS","url":"https://clinicaltrials.gov/study/NCT01349296","created_at":"2021-01-18T05:30:41.745Z","updated_at":"2024-07-02T16:37:31.819Z","phase":"Phase 1","brief_title":"BIBF 1120 and RAD001 in Solid Tumors - Phase I","source_id_and_acronym":"NCT01349296 - BARIS","lead_sponsor":"University of Cologne","biomarkers":" FGFR1","pipe":" | ","alterations":" FGFR1 amplification","tags":["FGFR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FGFR1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • nintedanib"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 07/01/2012","start_date":" 07/01/2012","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 05/01/2016","study_completion_date":" 05/01/2016","last_update_posted":"2016-05-20"}]